Get the Stockscreener App
0.00
100.00%
-0.675
Eagle Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.675
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$257.55M
Net Income/Loss:
$11.95M
P/E Ratio:
0.00
EPS:
0.9103
Net Cash Flow:
$-9.39M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.00
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Compare EGRX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
0.00 | 0 | 257.55M | 11.95M | -9.39M | 0.9103 |
TAK
Takeda Pharmaceutical Co Adr
|
18.91 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.27 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.34 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.22 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
494.56 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-01-18 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Mar-21-18 | Reiterated | Mizuho | Underperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | RBC Capital Mkts | Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-09-17 | Downgrade | Mizuho | Neutral → Underperform |
| Nov-16-16 | Downgrade | Mizuho | Buy → Neutral |
| Nov-03-16 | Upgrade | Mizuho | Neutral → Buy |
| Nov-03-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-26-16 | Reiterated | Mizuho | Buy |
| Aug-16-16 | Reiterated | Mizuho | Neutral |
| Jun-20-16 | Downgrade | Mizuho | Buy → Neutral |
| May-10-16 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-18-16 | Reiterated | Mizuho | Buy |
| Feb-26-16 | Reiterated | Mizuho | Buy |
| Dec-09-15 | Initiated | Mizuho | Buy |
| Jul-29-15 | Reiterated | Piper Jaffray | Overweight |
View All
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight - PR Newswire UK
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Berkshire Eagle
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements - Barchart.com
Glancy Prongay Wolke & Rotter LLP, as Lead Counsel, - GlobeNewswire
Eagle Pharma $9.5M Investor Deal Gets Final OK - Law360
Eagle’s $9.5 Million Investor Settlement Gets Court Approval - Bloomberg Law News
Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Rezolute Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results - Eagle-Tribune
Elite Pharmaceuticals, Inc. (ELTP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eagle Pharmaceuticals Shareholder Notice - TMX Newsfile
Vasopressin Market Overview: Major Segments, Strategic Developments, and Leading Companies - openPR.com
Market Trend Insights: The Impact of Recent Advances on the Hypoparathyroidism Market - openPR.com
In-Depth Examination of Segments, Industry Developments, and Key Players in the Docetaxel Market - openPR.com
Emerging Growth Patterns Driving Expansion in the Beta Blockers Market - openPR.com
Leading Companies Fueling Growth and Innovation in the Antiemetics and Antinauseants Market - openPR.com
EAGLE PHARMACEUTICALS INC Revenue Breakdown – OTC:EGRX - TradingView
Price to earnings forward of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
Amphastar Pharmaceuticals, Inc. (AMPH) stock price, news, quote and history - Yahoo Finance Australia
Price to book forward of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
Enterprise value to revenue forward of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
Enterprise value to EBITDA forward of Eagle Pharmaceuticals, Inc. – LSX:A1XEDS - TradingView
Price to sales forward of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
Enterprise value to EBIT forward of Eagle Pharmaceuticals, Inc. – LSX:A1XEDS - TradingView
Price to book forward of Eagle Pharmaceuticals, Inc. – LSX:A1XEDS - TradingView
MSN Money - MSN
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee - TMX Newsfile
Eagle Pharmaceuticals outlines its niche role in US hospital drugs - Ad-hoc-news.de
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - Eagle-Tribune
Kroger Is Buying This Family-Owned Supermarket For $1.65 Billion, Promising To Bring Customers 'Affordable Prices' - Yahoo Finance
Kroger buying regional grocer Giant Eagle in a deal valued at $1.65 billion - Yahoo Finance
Kroger to Buy Food & Pharmacy Retailer Giant Eagle for $1.65 Billion - WSJ
Kroger Announces Agreement to Acquire Giant Eagle - PR Newswire
Eagle Pharmaceuticals, Inc. Actuals & Estimates (OTC:EGRX) - TradingView
Eagle Pharmaceuticals $9.5M Securities Class Action Settlement - Claim Depot
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - Eagle-Tribune
Why Agnico Eagle Mines Limited stock is rising today - Wealth Awesome
Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight - 富途牛牛
Elite Laboratories Inc, AbbVie Inc, Par Health USA LLC, Sunstar Americas Inc, eVenus Pharmaceutical Lab Inc, Navinta LLC, PTS Consulting LLC, Makro Technologies Inc, Eagle Pharmaceuticals Inc, CMC GMP LLC Withdraw Approval Of 16 Abbreviated Ne - marketscreener.com
Eagle Point Credit Company (NYSE: ECC) converts to statutory trust; listings unchanged - Stock Titan
Eagle Health Investments LP Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Agnico Eagle Mines (AEM) To Begin Redevelopment Of The Hope Bay Mine With $2.4 Billion Investment - Yahoo Finance
Eagle Materials Inc. Q4 2026 Earnings Call Summary - Yahoo Finance
Number of shareholders of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
RVPH Stock Price and Chart — OTC:RVPH - TradingView
Eagle Pharmaceuticals stock (US2698191026): Recent SEC filings highlight ongoing developments - AD HOC NEWS
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise - Seeking Alpha
Eagle Pharmaceuticals Deadline Alert - TMX Newsfile
Emerging Sub-Segments Transforming the Vasopressin Market Landscape - openPR.com
Agnico Eagle Mines (AEM) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.01%
1.23%
Cap:
|
Volume (24h):